Company Description

Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States.

It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease.

The company was incorporated in 2016 and is headquartered in Mountain View, California.